US29405E2081 - Common Stock
ENVERIC BIOSCIENCES INC
NASDAQ:ENVB (4/19/2024, 7:00:02 PM)
After market: 0.8615 -0.02 (-2.17%)0.8806
-0.06 (-6.12%)
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. The company is headquartered in Naples Florida, Florida and currently employs 25 full-time employees. The company went IPO on 2009-07-21. The firm is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The firm through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The firm's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The firm is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.
ENVERIC BIOSCIENCES INC
4851 Tamiami Trail N, Suite 200
Naples Florida FLORIDA 34103
P: 12393021707
CEO: David Johnson
Employees: 25
Website: https://www.enveric.com/
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Here you can normally see the latest stock twits on ENVB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: